| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 323,50 | 324,80 | 28.02. | |
| 327,50 | 329,55 | 27.02. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 349,00 | 10 | |||
| 338,10 | 1 | |||
| 331,50 | 6 | |||
| 331,40 | 6 | |||
| 331,30 | 10 | |||
| 330,00 | 100 | |||
| 329,65 | 15 | |||
| 329,60 | 15 | |||
| 329,45 | 26 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/amg.htm [/URL] | ||||
| 26 | 328,45 | |||
| 10 | 326,70 | |||
| 6 | 326,60 | |||
| 6 | 326,50 | |||
| 1.053 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.101 | 0,172 | 189 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 27.02.2026 | 17:10:11 | 327,40 | 1 |
| 27.02.2026 | 16:55:46 | 327,80 | 6 |
| 27.02.2026 | 16:43:09 | 327,75 | 34 |
| 27.02.2026 | 15:42:42 | 324,80 | 4 |
| 27.02.2026 | 15:02:42 | 320,90 | 3 |
| 27.02.2026 | 14:01:39 | 320,00 | 40 |
| 27.02.2026 | 13:55:34 | 320,70 | 4 |
| 27.02.2026 | 13:55:34 | 320,65 | 35 |
| 27.02.2026 | 13:45:18 | 318,80 | 10 |
| 27.02.2026 | 13:45:18 | 318,80 | 20 |
| 27.02.2026 | 12:22:35 | 318,40 | 2 |
| 27.02.2026 | 09:07:26 | 320,80 | 1 |
| Tagesumsatz Xetra | +10,15 +3,18 % | 212 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Is Amgen Stock Outperforming the Dow? | 12 | Barchart.com | ||
| Di | NSE - AMGEN INC - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 4 | SEC Filings | ||
| Mo | If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today | 7 | Benzinga.com | ||
| AMGEN Aktie jetzt für 0€ handeln | |||||
| 20.02. | The Analyst Verdict: Amgen In The Eyes Of 18 Experts | 20 | Benzinga.com | ||
| 20.02. | Barclays initiates Amgen stock coverage with Equalweight rating | 6 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Sa | Shortseller-Positionen aktuell: Auto1, Energiekontor, freenet, Gerresheimer, Puma, Qiagen, TeamViewer | 4investors | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| Sa | BioMarin Pharmaceutical Inc.: U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) | PR Newswire | Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study
PALYNZIQ is the... ► Artikel lesen | |
| Sa | DBV Technologies S.A.: DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting | GlobeNewswire (Europe) | Châtillon, France, February 28, 2026
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
Approximately 83% of children treated... ► Artikel lesen | |
| Sa | Wegweisende News: NurExone - Pionier der regenerativen neuronalen Medizin! | bullVestor | ||
| Fr | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome | GlobeNewswire (Europe) | SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics... ► Artikel lesen |